Brochure
Animal drug discovery and in vivo evaluation
Antibody Engineering and
in vivo Pharmacology for
Animal Drug Development
As pets increasingly become indispensable family members globally, the rising pet econo-
my drives demand for advanced healthcare solutions. Cancer remains a critical threat,
affecting 25% of dogs and 20-30% of cats in their lifetimes, with 6 million annual canine
and 3 million feline cancer cases worldwide. Despite this urgency, the veterinary drug
market allocates <20% to specialized pet therapeutics, leaving vast unmet needs. Bridging
this gap requires innovative biologics tailored to companion animals.
Current cross-species antibody therapies face critical limitations: while 70-80% sequence
homology exists between human and pet disease targets, human-derived antibodies
rarely achieve functional equivalence in pets. Chimeric antibodies often trigger immuno-
genicity, compromising efficacy and safety. Species-specific monoclonal antibodies (e.g.,
fully canine/feline) represent the future of precision pet medicine—yet few platforms
address the unique challenges of antibody caninization & felinization and animal disease
models. This is where our expertise transforms possibilities into life-saving solutions.
Service Highlights
20+
10+
caninization/felinization projects
disease models of dogs and cats
Advanced mutation strategy
Structural modelling
Unique precise mutagenesis library (PML)
and FASEBA screening technology
Extensive experience in establishing
animal models
Multiple ready-to-use induction disease models
Availability of spontaneous disease animal recruitment
for simulating pet clinical trials
1
Antibody Caninization & Felinization
Rat sequence
Dog sequence
Rat mAb
Rat - dog chimeric mAb
Caninized mAb
Complementarity determining region of rat
Schematic Diagram of Caninization & Felinization
Search parental sequences against IMGT/NCBI database
Homology modeling of parental antibody Fv fragments
1
2
3
4
5
Design stepwise incorporation of one or more back mutations
in the grafted antibody sequence
Select one Cannie/Feline acceptor for VH/VL with the highest
identity to parental counterparts
Compare antibody sequences near CDRs, canonical residues,
loop interactions, and foundation cores
Case Study
Antibody Caninization
Antibody ka (1/s) kd (1/s) KD (1/s)
Antibody Felinization
Antibody ka (1/s) kd (1/s) KD (1/s)
Chimeric 2.07E+06 3.66E-04 1.77E-10
Variant 1 1.87E+06 3.02E-04 1.62E-10
Variant 2 1.67E+06 3.36E-04 2.01E-10
Variant 3 2.01E+06 4.66E-04 2.32E-10
Chimeric 5.35E+05 2.93E-04 5.47E-10
Variant 1 5.09E+05 2.25E-04 4.42E-10
Variant 2 5.01E+05 2.46E-04 4.92E-10
Variant 3 4.48E+05 1.83E-04 4.08E-10
The antibody canonization/felinization projects were successfully delivered, and canonized/
felinized antibodies with an affinity comparable to that of chimeric antibodies (10-10) were
obtained.
2
Canine/Feline Antibody Affinity Maturation
Precise
Affinity
matured IgG
production &
characteriza-
tion
Combinatorial
FASEBA
screening &
SPR affinity
ranking
Site-Saturation
Mutagenesis
Library (PML)
construction
library
construction &
FASEBA
Modelling &
Design
screening
FA
S
Fast
Screening of
E
Expression
B
Biophysical-properties
Affinity
A
Biacore 8K
Biacore T200
FASEBA High-throughput Screening Platform
Case Study
Feline Antibody Affinity Maturation
Antibody ka (1/s) kd (1/s) KD (M)
Feline Antibody Affinity Maturation
Antibody ka (1/s) kd (1/s) KD (M)
Canine-WT 1.23E+05 1.10E-03 8.92E-09
Variant 1 2.02E+05 5.23E-05 2.59E-10
Variant 2 6.74E+05 1.87E-05 2.78E-11
Variant 3 3.80E+05 3.80E-05 5.29E-11
Feline WT 6.49E+04 1.17E-04 1.80E-09
Variant 1 7.20E+04 1.09E-05 1.52E-10
Variant 2 8.43E+04 1.25E-05 1.48E-10
Variant 3 8.87E+04 4.40E-06 4.96E-11
Canine Antibody: The affinity of the canine-derived antibody was successfully increased
by 302 times, from 8*10-09 to 2*10-11.
Feline Antibody: The affinity of the feline-derived antibody was successfully increased by
36 times, from 1*10-09 to 4*10-11.
3
In vivo Evaluation
Disease models of dogs
Disease models of cats
Indication
Modeling method
Indication
Modeling method
Formalin induction model; Kaolin
induction model
T1DM
STZ induction model
Pain
High fat
diet+STZ+operation
Alloxan induction model; STZ
induction model
T2DM
T1DM
Calculus
Hyperoxaluria model
FIPV infection
FIPV infection model
MIA induction model
Atopic
dermatitis
MC903 induced model; Cytokine-
induced pruritus model
Osteoarthritis
Obesity
Osteoarthritis
Leukopenia
MIA induction model
Spontaneous obese
model
Cyclophosphamide-induced
myeloablative model
Canine osteoarthritis model
X-ray measurement
Model
Pain measurement
700
Baseline
(Modeling, MIA, QW*4W)
600
500
400
300
0W 1W
2W 3W
(Administration) (End point)
Model group
Drug group
12W
8W
Modeling Administration
Based on the MIA intra-articular injection, the canine osteoarthritis model was induced
and effectively alleviated by drug treatment.
Feline T1DM model
Drug treatment
Model establishment
20
15
10
5
15
10
5
(Modeling, STZ, Single dose)
RGB>11.1mmol/L
0D
(Modelling completed)
0
0
12~14D
Days post administration
Days post treatment
STZ was used to induce T1DM model in cats, and blood glucose was effectively reduced
by drug treatment.
4
ProBio Inc.
Building 9, 311 Pennington Rocky Hill Rd,
Pennington, NJ